FDA approves J&J's prostate cancer drug Erleada in new use, ...

The FDA has approved Johnson & Johnson’s prostate cancer drug Erleada (apalutamide) for patients whose prostate cancer has spread.

FDA starts quick review of Astellas/Seattle Genetics’ bladde...

Astellas tests gamification ideas with Japanese universities

Astellas has teamed up with Tokyo University of the Arts and Yokohama City University to create and commercialise new digital healthcare solutions using gamification.

Astellas pushes non-hormonal menopause drug into phase 3

Bayer aims at J&J and Pfizer with new prostate cancer drug

The FDA has approved Bayer and Orion’s prostate cancer drug darolutamide in the early stages of the disease as it takes on rivals such as Johnson & Johnson.

EMA starts review of Xtandi in hormone-sensitive prostate ca...